

Alessandro Serretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9270708/publications.pdf>

Version: 2024-02-01

735
papers

33,429
citations

6613

79
h-index

8630

146
g-index

831
all docs

831
docs citations

831
times ranked

26740
citing authors

#	ARTICLE	IF	CITATIONS
1	Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank. <i>Psychological Medicine</i> , 2023, 53, 3000-3008.	4.5	9
2	Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 1267-1274.	1.4	2
3	Venlafaxine and O-desmethylenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 183-190.	2.6	5
4	Epigenetic Basis of Psychiatric Disorders: A Narrative Review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 302-315.	1.4	4
5	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	2.2	31
6	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022, 296, 485-492.	4.1	3
7	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. <i>Biological Psychiatry</i> , 2022, 91, 313-327.	1.3	114
8	Seasonality in Major Depressive Disorder: Effect of Sex and Age. <i>Journal of Affective Disorders</i> , 2022, 296, 111-116.	4.1	9
9	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.7	19
10	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	4.8	3
11	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. <i>International Clinical Psychopharmacology</i> , 2022, 37, 38-45.	1.7	9
12	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2022, 55, 112-157.	0.7	7
13	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	3.2	14
14	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. <i>European Neuropsychopharmacology</i> , 2022, 56, 100-111.	0.7	5
15	Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders. <i>Translational Psychiatry</i> , 2022, 12, 59.	4.8	39
16	Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features. <i>International Clinical Psychopharmacology</i> , 2022, 37, 166-172.	1.7	5
17	Polygenic risk scores for neuropsychiatric, inflammatory, and cardio-metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2022, 189, 74-85.	1.7	8
18	Precision medicine in mood disorders. , 2022, 1, .		2

#	ARTICLE	IF	CITATIONS
19	The Influence of 5-HTTLPR, BDNF Rs6265 and COMT Rs4680 Polymorphisms on Impulsivity in Bipolar Disorder: The Role of Gender. <i>Genes</i> , 2022, 13, 482.	2.4	8
20	Psychopharmacology: past, present and future. <i>International Clinical Psychopharmacology</i> , 2022, 37, 82-83.	1.7	3
21	Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence. <i>International Clinical Psychopharmacology</i> , 2022, 37, 29-37.	1.7	7
22	Imputed expression of schizophrenia-associated genes and cognitive measures in patients with schizophrenia. <i>Molecular Genetics & Genomic Medicine</i> , 2022, 10, e1942.	1.2	6
23	Depression, antidepressants, and insulin resistance: which link?. <i>European Neuropsychopharmacology</i> , 2022, 60, 4-6.	0.7	16
24	The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2022, 60, 55-75.	0.7	6
25	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. <i>European Neuropsychopharmacology</i> , 2022, 60, 91-99.	0.7	9
26	Persistence of suicidal ideation within acute phase treatment of major depressive disorder: analysis of clinical predictors. <i>International Clinical Psychopharmacology</i> , 2022, 37, 193-200.	1.7	10
27	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. <i>Journal of Affective Disorders</i> , 2022, 312, 225-234.	4.1	2
28	The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?. <i>International Clinical Psychopharmacology</i> , 2022, 37, 263-275.	1.7	9
29	Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. <i>Journal of Clinical Medicine</i> , 2022, 11, 3935.	2.4	7
30	The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls. <i>Comprehensive Psychiatry</i> , 2022, 117, 152335.	3.1	2
31	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110050.	4.8	21
32	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021, 279, 722-729.	4.1	7
33	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110170.	4.8	36
34	Precision psychiatry in clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 19-27.	2.4	25
35	Irritable Mood and Subthreshold Hypomanic Episodes Correlate with More Severe Major Depression. <i>Neuropsychobiology</i> , 2021, 80, 425-436.	1.9	6
36	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 46-52.	2.0	2

#	ARTICLE	IF	CITATIONS
37	A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 160-165.	2.0	3
38	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. <i>Molecular Psychiatry</i> , 2021, 26, 3363-3373.	7.9	66
39	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. <i>Nature Genetics</i> , 2021, 53, 817-829.	21.4	629
40	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	4.1	4
41	Genetic underpinnings of sociability in the general population. <i>Neuropsychopharmacology</i> , 2021, 46, 1627-1634.	5.4	18
42	Precision psychiatry. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	1.7	0
43	The association of childhood trauma, lifetime stressful events and general psychopathological symptoms in euthymic bipolar patients and healthy subjects. <i>Journal of Affective Disorders</i> , 2021, 289, 66-73.	4.1	7
44	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. <i>Neuropsychopharmacology</i> , 2021, 46, 1821-1829.	5.4	27
45	Pharmacogeneticâ€Guided Treatment of Depression: Realâ€World Clinical Applications, Challenges, and Perspectives. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 573-581.	4.7	11
46	Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment. <i>Mindfulness</i> , 2021, 12, 2059-2075.	2.8	1
47	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2021, 26, 5797-5811.	7.9	30
48	Sexâ€related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	4.1	18
49	Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110266.	4.8	53
50	Melancholic features in major depression â€ a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	4.8	17
51	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	2.4	1
52	Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 694-696.	1.4	3
53	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	3.1	14
54	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	2.1	2

#	ARTICLE	IF	CITATIONS
55	P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2021, 53, S646-S647.	0.7	0
56	Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants: A Pilot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 801738.	2.6	3
57	Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. <i>Neuroscience Letters</i> , 2020, 726, 133651.	2.1	14
58	Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder. <i>Journal of Affective Disorders</i> , 2020, 261, 181-186.	4.1	11
59	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>American Journal of Psychiatry</i> , 2020, 177, 76-92.	7.2	83
60	Genetics of resilience: Implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 77-94.	1.7	54
61	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. <i>Molecular Biology Reports</i> , 2020, 47, 191-200.	2.3	6
62	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 901-910.	3.2	8
63	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109835.	4.8	32
64	Cortico-limbic functional connectivity mediates the effect of early life stress on suicidality in bipolar depressed 5-HTTLPR*s carriers. <i>Journal of Affective Disorders</i> , 2020, 263, 420-427.	4.1	13
65	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , 2020, 11, 575540.	3.5	46
66	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.7	14
67	Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. <i>International Clinical Psychopharmacology</i> , 2020, 35, 233-242.	1.7	22
68	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	2.1	5
69	Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 200-202.	1.4	6
70	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020, 10, 50.	4.8	33
71	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 720, 134754.	2.1	9
72	The black sheep of the family- whole-exome sequencing in family of lithium response discordant bipolar monozygotic twins. <i>European Neuropsychopharmacology</i> , 2020, 34, 19-27.	0.7	8

#	ARTICLE	IF	CITATIONS
73	New generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRI, MASSAs, NDRI, and others. Medicinal Research Reviews, 2020, 40, 1794-1832.	10.5	34
74	Antidepressants: Indications, Contraindications, Interactions, and Side Effects. , 2020, , 1-38.		3
75	Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. Clinical Psychopharmacology and Neuroscience, 2020, 18, 1-9.	2.0	23
76	<i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 231-240.	2.0	5
77	How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. Clinical Psychopharmacology and Neuroscience, 2020, 18, 484-492.	2.0	14
78	The search for personalized antidepressant treatments: what have we learned and where are we going. Pharmacogenomics, 2020, 21, 1095-1100.	1.3	2
79	White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress. Molecular Neurobiology, 2019, 56, 702-710.	4.0	37
80	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 375-387.	4.8	35
81	Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 23-29.	4.8	13
82	Results of the European Group for the Study of Resistant Depression (GSRD) as a basis for further research and clinical practice. World Journal of Biological Psychiatry, 2019, 20, 427-448.	2.6	89
83	Is Pharmacogenetics Useful in Antidepressant Treatment?. Clinical Pharmacology and Therapeutics, 2019, 106, 916-918.	4.7	2
84	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology, 2019, 29, 971-985.	0.7	93
85	F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S1166-S1167.	0.7	0
86	12 GENETIC UNDERPINNINGS OF SOCIABILITY. European Neuropsychopharmacology, 2019, 29, S65.	0.7	0
87	M67 PSYCHIATRIC DISORDERS AND SLC6A4 GENE VARIANTS: POSSIBLE MODULATION OF ALCOHOL DEPENDENCE AND ALZHEIMER'S DISEASE. European Neuropsychopharmacology, 2019, 29, S202-S203.	0.7	0
88	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14
89	High occupational level is associated with poor response to the treatment of depression: A replication study. European Neuropsychopharmacology, 2019, 29, 349-355.	0.7	3
90	Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. Neuropsychobiology, 2019, 78, 79-85.	1.9	9

#	ARTICLE	IF	CITATIONS
91	WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S934-S935.	0.7	0
92	The brief assessment of cognition in affective disorders: Normative data for the Italian population. Journal of Affective Disorders, 2019, 252, 245-252.	4.1	8
93	<i>FKBP5</i> Gene Variants May Modulate Depressive Features in Bipolar Disorder. Neuropsychobiology, 2019, 78, 104-112.	1.9	4
94	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109638.	4.8	20
95	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	21.4	1,191
96	Comorbid hypertension in patients with major depressive disorder “ Results from a European multicenter study. European Neuropsychopharmacology, 2019, 29, 777-785.	0.7	18
97	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis. European Neuropsychopharmacology, 2019, 29, S278-S279.	0.7	0
98	Temperament and character influence on depression treatment outcome. Journal of Affective Disorders, 2019, 252, 464-474.	4.1	27
99	Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder. European Neuropsychopharmacology, 2019, 29, S378-S379.	0.7	0
100	Predominant polarity in bipolar disorder patients: The COPE bipolar sample. Journal of Affective Disorders, 2019, 250, 43-50.	4.1	17
101	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, 2019, 249, 410-417.	4.1	12
102	M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S206-S207.	0.7	0
103	Personalized and precision medicine as informants for treatment management of bipolar disorder. International Clinical Psychopharmacology, 2019, 34, 189-205.	1.7	17
104	Attrition in treatment-resistant depression. International Clinical Psychopharmacology, 2019, 34, 161-169.	1.7	0
105	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	28.9	935
106	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. Neuropsychobiology, 2019, 77, 67-72.	1.9	13
107	Relating constructs of attention and working memory to social withdrawal in Alzheimer’s disease and schizophrenia: issues regarding paradigm selection. Neuroscience and Biobehavioral Reviews, 2019, 97, 47-69.	6.1	22
108	Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature. Human Molecular Genetics, 2019, 28, 972-979.	2.9	17

#	ARTICLE	IF	CITATIONS
109	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	2.8	44
110	Duloxetine plasma level and antidepressant response. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 127-132.	4.8	23
111	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , 2019, 49, 49-54.	4.5	8
112	Quantitative neurosymptomatology: Linking quantitative biology to neuropsychiatry. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 1-2.	6.1	8
113	Social brain, social dysfunction and social withdrawal. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 10-33.	6.1	216
114	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 78-88.	4.5	92
115	A quantitative approach to neuropsychiatry: The why and the how. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 3-9.	6.1	63
116	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 93-104.	2.1	32
117	Pharmacogenetics and Depression: A Critical Perspective. <i>Psychiatry Investigation</i> , 2019, 16, 645-653.	1.6	17
118	Psychotic Features in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	28
119	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C</i> , <i>CHRNA7</i> and <i>MAPK1</i> . <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 364-368.	2.0	12
120	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 539-549.	2.1	54
121	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 401-412.	4.5	37
122	Deiodinases, Organic Anion Transporter Polypeptide Polymorphisms, and Thyroid Hormones in Patients with Myocardial Infarction. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 270-278.	0.7	7
123	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 273-286.	2.3	5
124	Highlights on Pharmacogenetics and Pharmacogenomics in Depression. , 2018, , 3-16.		0
125	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018, 28, 752-760.	0.7	47
126	Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. <i>Molecular Psychiatry</i> , 2018, 23, 133-142.	7.9	247

#	ARTICLE	IF	CITATIONS
127	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , 2018, 227, 254-259.	4.1	6
128	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 203-210.	4.8	31
129	Expansion and further delineation of the <i>SETD5</i> phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance. <i>Clinical Genetics</i> , 2018, 93, 752-761.	2.0	23
130	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 62-74.	2.3	3
131	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018, 227, 777-786.	4.1	32
132	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: <i>5-HTTLPR</i> and other variants. <i>Human Psychopharmacology</i> , 2018, 33, e2682.	1.5	7
133	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1305-1313.	0.7	15
134	Brexipiprazole: a step forward for precision medicine in resistant depression. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1817-1819.	1.8	2
135	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. <i>Advances in Therapy</i> , 2018, 35, 1656-1670.	2.9	14
136	Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 36-44.	4.8	39
137	Antidepressant induced weight gain. <i>BMJ: British Medical Journal</i> , 2018, 361, k2151.	2.3	6
138	A Glutamate Transporter EAAT1 Gene Variant Influences Amygdala Functional Connectivity in Bipolar Disorder. <i>Journal of Molecular Neuroscience</i> , 2018, 65, 536-545.	2.3	37
139	The association between electrodermal activity (EDA), depression and suicidal behaviour: A systematic review and narrative synthesis. <i>BMC Psychiatry</i> , 2018, 18, 22.	2.6	107
140	Pharmacogenetics in Psychiatry. <i>Advances in Pharmacology</i> , 2018, 83, 297-331.	2.0	31
141	22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders. <i>Lancet Psychiatry</i> , 2018, 5, 531-532.	7.4	1
142	Refining Prediction in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16m11385.	2.2	76
143	The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 1-6.	2.0	56
144	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 469-480.	2.0	35

#	ARTICLE	IF	CITATIONS
145	Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics. World Journal of Biological Psychiatry, 2017, 18, 492-505.	2.6	48
146	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Advances in Therapy, 2017, 34, 713-724.	2.9	15
147	Maoa and Maob polymorphisms and personality traits in suicide attempters and healthy controls: a preliminary study. Psychiatry Research, 2017, 249, 212-217.	3.3	5
148	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. Journal of Psychiatric Research, 2017, 91, 1-13.	3.1	77
149	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of Psychiatric Research, 2017, 89, 97-104.	3.1	17
150	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 723-735.	3.2	21
151	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International Clinical Psychopharmacology, 2017, 32, 235-248.	1.7	19
152	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 482-490.	2.5	10
153	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	2.9	3
154	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. European Neuropsychopharmacology, 2017, 27, 625-632.	0.7	19
155	Nine differentially expressed genes from a post mortem study and their association with suicidal status in a sample of suicide completers, attempters and controls. Journal of Psychiatric Research, 2017, 91, 98-104.	3.1	6
156	Genes Involved In Neurodevelopment, Neuroplasticity And Bipolar Disorder: Cacna1c, Chrna1 And MAPK1. European Neuropsychopharmacology, 2017, 27, S451-S452.	0.7	0
157	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. International Journal of Neuropsychopharmacology, 2017, 20, 782-787.	2.1	10
158	Cariprazine specificity profile in the treatment of acute schizophrenia. International Clinical Psychopharmacology, 2017, 32, 309-318.	1.7	27
159	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 757-764.	1.7	38
160	Escitalopram plasma levels and antidepressant response. European Neuropsychopharmacology, 2017, 27, 940-944.	0.7	45
161	Prescribing patterns of psychiatric drugs in major depressive disorder – Findings from a large European multicenter, cross-sectional study. European Psychiatry, 2017, 41, S367-S367.	0.2	0
162	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World Journal of Biological Psychiatry, 2017, 18, 5-28.	2.6	75

#	ARTICLE	IF	CITATIONS
163	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, S583.	0.7	0
164	Potential genes behind the difference between bipolar I and bipolar II disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, S836-S837.	0.7	0
165	Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, S1057-S1058.	0.7	0
166	Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. <i>Neuropsychobiology</i> , 2017, 76, 209-221.	1.9	11
167	Genetics and pharmacogenetics of mood disorders. <i>Psychiatria Polska</i> , 2017, 51, 197-203.	0.5	11
168	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 215-222.	2.2	73
169	Evidence based criteria for the antidepressant choice. <i>Dusunen Adam</i> , 2017, , 1-5.	0.2	0
170	Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 283-289.	2.0	17
171	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment â€” a European multicentre study. <i>International Clinical Psychopharmacology</i> , 2016, 31, 1-7.	1.7	19
172	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. <i>Neuropsychobiology</i> , 2016, 74, 159-168.	1.9	23
173	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. <i>European Neuropsychopharmacology</i> , 2016, 26, S240-S241.	0.7	0
174	Epidemiology of psychopharmacological options in unipolar major depression in European tertiary psychiatric treatment centers. <i>European Neuropsychopharmacology</i> , 2016, 26, S417-S418.	0.7	0
175	A meta-analysis of cognitive performance in melancholic versus non-melancholic unipolar depression. <i>Journal of Affective Disorders</i> , 2016, 201, 15-24.	4.1	49
176	Possible biomarkers modulating haloperidol efficacy and/or tolerability. <i>Pharmacogenomics</i> , 2016, 17, 507-529.	1.3	0
177	Clinical factors related to schizophrenia relapse. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 54-69.	2.4	31
178	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv125.	2.1	26
179	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. <i>Neuropsychobiology</i> , 2016, 73, 160-168.	1.9	11
180	Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. <i>Psychiatry Research</i> , 2016, 240, 421-430.	3.3	145

#	ARTICLE	IF	CITATIONS
181	Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2016, 370, 162-166.	0.6	12
182	High occupational level is associated with poor response to treatment of depression. <i>European Neuropsychopharmacology</i> , 2016, 26, 1320-1326.	0.7	8
183	Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. <i>Neuropsychobiology</i> , 2016, 74, 1-7.	1.9	15
184	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. <i>BMC Psychiatry</i> , 2016, 16, 172.	2.6	16
185	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1960-1971.	0.7	50
186	Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?. <i>Evidence-Based Mental Health</i> , 2016, 19, e25-e25.	4.5	0
187	Progress and prospects in pharmacogenetics of antidepressant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1157-1168.	3.3	30
188	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 27-31.	1.4	11
189	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , 2016, 204, 54-58.	4.1	30
190	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. <i>BMC Psychiatry</i> , 2016, 16, 106.	2.6	24
191	Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis. <i>Molecular Neurobiology</i> , 2016, 53, 2065-2081.	4.0	28
192	Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2016, 26, 163-185.	0.7	54
193	5-HTTLPR and gender differences in affective disorders: A systematic review. <i>Journal of Affective Disorders</i> , 2016, 190, 193-207.	4.1	52
194	Clinical and genetic factors associated with suicide in mood disorder patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 181-193.	3.2	32
195	The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades. <i>Journal of Affective Disorders</i> , 2016, 190, 429-438.	4.1	13
196	Remifentanyl in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 703-717.	3.2	24
197	Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs. , 2016, , 39-54.		1
198	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. <i>Neuropsychobiology</i> , 2016, 73, 35-42.	1.9	21

#	ARTICLE	IF	CITATIONS
199	Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders. <i>Metabolic Brain Disease</i> , 2016, 31, 183-189.	2.9	6
200	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016, 189, 224-232.	4.1	73
201	Genetics of long-term treatment outcome in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 17-24.	4.8	39
202	Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. <i>Psychiatry Investigation</i> , 2016, 13, 247.	1.6	15
203	The Role of Pharmacogenetics in Pharmacovigilance of Psychotropic Drugs. , 2016, , 121-146.		0
204	Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant, and Mood-Stabilizing Drugs. , 2016, , 111-117.		0
205	P1.a.023 Impact of a SNP in SIGMAR1 on major depression, bipolar disorder and treatment response. <i>European Neuropsychopharmacology</i> , 2015, 25, S170-S171.	0.7	0
206	P.1.a.034 Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease: a systematic review. <i>European Neuropsychopharmacology</i> , 2015, 25, S175-S176.	0.7	0
207	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. <i>Neuropsychobiology</i> , 2015, 72, 118-125.	1.9	8
208	Alcohol Dependence and Genetic Variability in the Serotonin Pathway among Currently and Formerly Alcohol-Dependent Males. <i>Neuropsychobiology</i> , 2015, 72, 57-64.	1.9	12
209	Low-activity alleles of the MAOA gene are associated with measures of hostility. <i>Psychiatric Genetics</i> , 2015, 25, 215.	1.1	1
210	Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 354-362.	1.5	15
211	CACNA1C gene and schizophrenia. <i>Psychiatric Genetics</i> , 2015, 25, 163-167.	1.1	21
212	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 220-227.	1.4	22
213	Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 296-303.	1.4	44
214	Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications. <i>Current Psychiatry Reports</i> , 2015, 17, 50.	4.5	69
215	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , 2015, 184, 51-59.	4.1	38
216	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150

#	ARTICLE	IF	CITATIONS
217	P.1.a.006 CACNA1C gene and schizophrenia: A case-control and pharmacogenetic study. European Neuropsychopharmacology, 2015, 25, S162.	0.7	1
218	Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics. Neuropsychobiology, 2015, 71, 218-224.	1.9	29
219	Cognitive markers of psychotic unipolar depression: A meta-analytic study. Journal of Affective Disorders, 2015, 174, 580-588.	4.1	50
220	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. Journal of Neural Transmission, 2015, 122, 43-58.	2.8	14
221	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. European Neuropsychopharmacology, 2015, 25, 441-453.	0.7	77
222	A molecular pathway analysis informs the genetic background at risk for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 59, 21-30.	4.8	20
223	Genetic Variability in CYP2E1 and Catalase Gene Among Currently and Formerly Alcohol-Dependent Male Subjects. Alcohol and Alcoholism, 2015, 50, 140-145.	1.6	28
224	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. World Journal of Biological Psychiatry, 2015, 16, 472-482.	2.6	15
225	A model to investigate SNPs' interaction in GWAS studies. Journal of Neural Transmission, 2015, 122, 145-153.	2.8	3
226	CHL1,ITGB3andSLC6A4gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. Pharmacogenomics, 2015, 16, 689-701.	1.3	22
227	The role of specific early trauma in adult depression: A meta-analysis of published literature. Childhood trauma and adult depression. European Psychiatry, 2015, 30, 665-680.	0.2	393
228	Genetic variability in tryptophan hydroxylase 2 gene in alcohol dependence and alcohol-related psychopathological symptoms. Neuroscience Letters, 2015, 604, 86-90.	2.1	12
229	Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls. Psychiatry Research, 2015, 228, 945-949.	3.3	24
230	Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 579-588.	3.2	5
231	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 174-186.	2.4	53
232	The Influence of AH11 Variants on the Diagnosis and Treatment Outcome in Schizophrenia. International Journal of Molecular Sciences, 2015, 16, 2517-2529.	4.1	11
233	Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics Journal, 2015, 15, 538-548.	2.0	34
234	Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. Journal of Affective Disorders, 2015, 179, 88-94.	4.1	44

#	ARTICLE	IF	CITATIONS
235	Predictors of switch from depression to mania in bipolar disorder. Journal of Psychiatric Research, 2015, 66-67, 45-53.	3.1	26
236	Personalized therapies in psychiatry: promises, pitfalls and perspectives. Journal of Neural Transmission, 2015, 122, 1-3.	2.8	9
237	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational Psychiatry, 2015, 5, e513-e513.	4.8	20
238	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. Psychiatry Research, 2015, 226, 474-483.	3.3	54
239	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2015, 64, 88-98.	3.1	47
240	Persistent benefits of slow titration of paroxetine in a six-month follow-up. Human Psychopharmacology, 2015, 30, 329-333.	1.5	2
241	P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder. European Neuropsychopharmacology, 2015, 25, S159-S160.	0.7	0
242	P.1.a.007 Four polymorphisms of SLC6A4 are novel predictors of SSRI/SNRI response in depressive disorder: sequencing analysis of SLC6A4. European Neuropsychopharmacology, 2015, 25, S162-S163.	0.7	1
243	Neuroticism, social network, stressful life events: Association with mood disorders, depressive symptoms and suicidal ideation in a community sample of women. Psychiatry Research, 2015, 226, 38-44.	3.3	31
244	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. International Journal of Neuroscience, 2015, 125, 336-343.	1.6	7
245	A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive recurrences during citalopram treatment. Journal of Neural Transmission, 2015, 122, 465-475.	2.8	3
246	The Neuropsychological Hypothesis of Antidepressant Drug Action Revisited. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1722-1739.	1.4	2
247	CRY1 Variations Impacts on the Depressive Relapse Rate in a Sample of Bipolar Patients. Psychiatry Investigation, 2015, 12, 118.	1.6	10
248	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. Clinical Psychopharmacology and Neuroscience, 2015, 13, 48-52.	2.0	15
249	Meet the Editorial Board:. Current Medicinal Chemistry, 2015, 22, 1169-1169.	2.4	0
250	Trait-aggressiveness and impulsivity: Role of psychological resilience and childhood trauma in a sample of male prisoners. Nordic Journal of Psychiatry, 2014, 68, 8-17.	1.3	23
251	Benefit of slow titration of paroxetine to treat depression in the elderly. Human Psychopharmacology, 2014, 29, 544-551.	1.5	5
252	Pharmacogenetics of Antidepressant Drugs. , 2014, , 543-562.		0

#	ARTICLE	IF	CITATIONS
253	Serious suicidal behaviors: Socio-demographic and clinical features in a multinational, multicenter sample. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 44-52.	1.3	19
254	Clozapine augmentation with amisulpride. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, E38-E39.	2.4	6
255	The genetics of vascular incidents associated with second-generation antipsychotic administration. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 75-90.	3.1	1
256	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. <i>Human Psychopharmacology</i> , 2014, 29, 388-391.	1.5	11
257	Genetic Variations within Metalloproteinases Impact on the Prophylaxis of Depressive Phases in Bipolar Patients. <i>Neuropsychobiology</i> , 2014, 69, 76-82.	1.9	6
258	Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 314-319.	1.5	28
259	Psychological Mechanisms of Mindfulness-Based Interventions. <i>Holistic Nursing Practice</i> , 2014, 28, 124-148.	0.7	88
260	Genetic modulation of personality traits. <i>International Clinical Psychopharmacology</i> , 2014, 29, 1-15.	1.7	78
261	Quetiapine Extended Release. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 303-306.	1.4	4
262	Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1-8.	2.1	32
263	Genomewide interaction and enrichment analysis on antidepressant response. <i>Psychological Medicine</i> , 2014, 44, 753-765.	4.5	7
264	P.3.015 Socio-demographic and clinical predictors of antidepressant remission and response in treatment resistant depression. <i>European Neuropsychopharmacology</i> , 2014, 24, S67-S68.	0.7	0
265	The association of personality trait on treatment outcomes in patients with chronic prostatitis/chronic pelvic pain syndrome: An exploratory study. <i>Journal of Psychosomatic Research</i> , 2014, 76, 127-133.	2.6	28
266	Family history of a mood disorder indicates a more severe bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 156, 178-186.	4.1	29
267	P.3.d.026 Pharmacogenetics of clozapine response and metabolic side effects: a comprehensive review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2014, 24, S536-S537.	0.7	0
268	Are Mindfulness-Based Interventions Effective for Substance Use Disorders? A Systematic Review of the Evidence. <i>Substance Use and Misuse</i> , 2014, 49, 492-512.	1.4	262
269	Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 567-577.	3.8	19
270	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. <i>Journal of Affective Disorders</i> , 2014, 168, 91-97.	4.1	15

#	ARTICLE	IF	CITATIONS
271	Influence of differentially expressed genes from suicide post-mortem study on personality traits as endophenotypes on healthy subjects and suicide attempters. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 423-432.	3.2	11
272	Effects of antipsychotic drugs on insight in schizophrenia. <i>Psychiatry Research</i> , 2014, 218, 20-24.	3.3	13
273	Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1093-1118.	3.3	14
274	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014, 14, 463-472.	2.0	41
275	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014, 18, 97-102.	2.4	19
276	P.6.b.002 Oxidative stress and expression of alcohol related psychopathological symptoms in alcohol dependent subjects. <i>European Neuropsychopharmacology</i> , 2014, 24, S664.	0.7	0
277	Modulation of a number of genes on personality traits in a sample of healthy subjects. <i>Neuroscience Letters</i> , 2014, 566, 320-325.	2.1	6
278	HSP70 polymorphisms in first psychotic episode drug-naïve schizophrenic patients. <i>Life Sciences</i> , 2014, 100, 133-137.	4.3	12
279	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , 2014, 55, 51-55.	3.1	8
280	P.3.018 Insomnia and somnolence induced by second-generation antidepressants during the treatment of major depression: a meta-analysis. <i>European Neuropsychopharmacology</i> , 2014, 24, S69-S70.	0.7	0
281	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. <i>Psychiatry Research</i> , 2014, 215, 799-800.	3.3	8
282	P.1.014 PPP3CC: a new candidate gene in antidepressant response. <i>European Neuropsychopharmacology</i> , 2014, 24, S14-S15.	0.7	0
283	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. <i>Journal of Psychiatric Research</i> , 2014, 56, 72-81.	3.1	27
284	From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 62-75.	1.9	46
285	Highlights from the latest articles in suicide research. <i>Personalized Medicine</i> , 2014, 11, 255-258.	1.5	0
286	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 481.	1.6	13
287	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 200.	1.6	2
288	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , 2014, 26, 243-53.	0.6	4

#	ARTICLE	IF	CITATIONS
289	Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. <i>Psychopharmacology</i> , 2013, 227, 509-519.	3.1	51
290	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 271-278.	4.8	38
291	Gene environment interaction studies in depression and suicidal behavior: An update. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2375-2397.	6.1	143
292	MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 393-403.	3.2	32
293	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 93-103.	3.2	24
294	The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 105-118.	3.2	96
295	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. <i>Journal of Neural Transmission</i> , 2013, 120, 1709-1715.	2.8	30
296	Serotonergic genes and suicide: A systematic review. <i>European Neuropsychopharmacology</i> , 2013, 23, 1125-1142.	0.7	109
297	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , 2013, 150, 649-652.	4.1	14
298	P.4.021 Genome-wide association analysis and pathway analysis in predicting antidepressant treatment response. <i>European Neuropsychopharmacology</i> , 2013, 23, S85.	0.7	0
299	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. <i>Psychiatry Research</i> , 2013, 209, 121-123.	3.3	22
300	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	7.2	579
301	Genetic modulation of borderline personality disorder: Systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2013, 47, 1275-1287.	3.1	44
302	Mindfulness: Top-down or bottom-up emotion regulation strategy?. <i>Clinical Psychology Review</i> , 2013, 33, 82-96.	11.4	328
303	Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 487-520.	1.7	77
304	The 5-HTTLPR Polymorphism and Posttraumatic Stress Disorder: A Meta-Analysis. <i>Journal of Traumatic Stress</i> , 2013, 26, 645-653.	1.8	82
305	The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1597-1610.	6.1	88
306	Temperamental and Genetic Predictors of Suicide Attempt and Self-Mutilation. <i>Neuropsychobiology</i> , 2013, 68, 250-257.	1.9	6

#	ARTICLE	IF	CITATIONS
307	Clinical, psychological and environmental predictors of prospective suicide events in patients with Bipolar Disorder. Journal of Psychiatric Research, 2013, 47, 1800-1808.	3.1	42
308	Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia. Genetic Testing and Molecular Biomarkers, 2013, 17, 504-507.	0.7	8
309	Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode. Journal of Psychiatric Research, 2013, 47, 162-167.	3.1	32
310	Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: A principal component analysis of lifetime pharmacological and biophysical treatment options. European Neuropsychopharmacology, 2013, 23, 263-275.	0.7	29
311	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 65-74.	3.2	16
312	Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. European Neuropsychopharmacology, 2013, 23, 1739-1746.	0.7	11
313	P.1.a.021 A molecular pathway analysis of the genes in 22q11.2 provides information on the genetic structure of psychosis. European Neuropsychopharmacology, 2013, 23, S171-S172.	0.7	0
314	S.25.03 Pharmacogenetics of efficacy and treatment side effects in bipolar disorder. European Neuropsychopharmacology, 2013, 23, S148.	0.7	0
315	P.2.f.015 A prospective study of escitalopram in treatment resistant depression not responding to venlafaxine. European Neuropsychopharmacology, 2013, 23, S403-S404.	0.7	0
316	P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. European Neuropsychopharmacology, 2013, 23, S540-S541.	0.7	0
317	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. European Neuropsychopharmacology, 2013, 23, 895-901.	0.7	28
318	Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. European Neuropsychopharmacology, 2013, 23, 612-621.	0.7	26
319	P.3.a.005 A deeper look onto schizophrenia mechanisms. Association with immunological related pathway. European Neuropsychopharmacology, 2013, 23, S424.	0.7	0
320	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. European Neuropsychopharmacology, 2013, 23, 887-894.	0.7	27
321	Clinical features and drug induced side effects in early versus late antidepressant responders. Journal of Psychiatric Research, 2013, 47, 1309-1318.	3.1	26
322	Antidepressants in elderly: Metaregression of double-blind, randomized clinical trials. Journal of Affective Disorders, 2013, 147, 1-8.	4.1	75
323	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. European Neuropsychopharmacology, 2013, 23, S168-S169.	0.7	0
324	P.2.f.025 Specificity profile of venlafaxine and sertraline in major depression: meta-regression of double-blind, randomized clinical trials. European Neuropsychopharmacology, 2013, 23, S409-S410.	0.7	0

#	ARTICLE	IF	CITATIONS
325	Authors' reply to "Recommendations for conducting mindfulness based cognitive therapy trials" Psychiatry Research, 2013, 207, 232-233.	3.3	0
326	P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples. European Neuropsychopharmacology, 2013, 23, S403.	0.7	0
327	P.2.c.010 The inflammatory genetic background and genetically disruption of lithium related molecular pathways in bipolar disorder patients. European Neuropsychopharmacology, 2013, 23, S360.	0.7	0
328	Social adjustment among treatment responder patients with mood disorders. Journal of Affective Disorders, 2013, 150, 961-966.	4.1	2
329	P.2.b.026 Social adjustment among therapy responder patients with mood disorders. European Neuropsychopharmacology, 2013, 23, S334.	0.7	0
330	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 385-391.	3.2	16
331	Shared genetics among major psychiatric disorders. Lancet, The, 2013, 381, 1339-1341.	13.7	70
332	Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability. Journal of Affective Disorders, 2013, 148, 316-322.	4.1	17
333	Pharmacogenetics in major depression: A comprehensive meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 183-194.	4.8	174
334	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. Journal of Psychopharmacology, 2013, 27, 616-628.	4.0	19
335	Impact of 5-HTTLPR Polymorphism on Alexithymia in Alcoholic Patients After Detoxification Treatment. Journal of Addiction Medicine, 2013, 7, 372-373.	2.6	4
336	Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder. Journal of International Medical Research, 2013, 41, 809-815.	1.0	7
337	TPH1, MAOA, Serotonin Receptor 2A and 2C Genes in Citalopram Response: Possible Effect in Melancholic and Psychotic Depression. Neuropsychobiology, 2013, 67, 41-47.	1.9	30
338	Newer antidepressants and panic disorder. International Clinical Psychopharmacology, 2013, 28, 33-45.	1.7	50
339	The Impact of Adverse Life Events on Clinical Features and Interaction with Gene Variants in Mood Disorder Patients. Psychopathology, 2013, 46, 384-389.	1.5	10
340	A Genetic Dissection of Antipsychotic Induced Movement Disorders. Current Medicinal Chemistry, 2013, 20, 312-330.	2.4	7
341	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. Journal of Clinical Psychopharmacology, 2013, 33, 131-132.	1.4	12
342	Potential Benefits of Slow Titration of Paroxetine Treatment in an Elderly Population. Journal of Clinical Psychopharmacology, 2013, 33, 565-569.	1.4	2

#	ARTICLE	IF	CITATIONS
343	Genetics of Serotonin Receptors and Depression: State of the Art. <i>Current Drug Targets</i> , 2013, 14, 531-548.	2.1	26
344	Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines. <i>Current Alzheimer Research</i> , 2013, 10, 154-164.	1.4	12
345	No Effect of Serotonergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. <i>Psychiatry Investigation</i> , 2013, 10, 180.	1.6	20
346	A Genetic Dissection of Antipsychotic Induced Movement Disorders. <i>Current Medicinal Chemistry</i> , 2013, 20, 312-330.	2.4	2
347	A genetic dissection of antipsychotic induced movement disorders. <i>Current Medicinal Chemistry</i> , 2013, 20, 312-30.	2.4	7
348	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , 2013, 25, 97-106.	0.6	5
349	Bipolar disorder: "pure" versus mixed depression over a 1-year follow-up. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 113-120.	2.4	7
350	Quetiapine for bipolar depression. <i>International Clinical Psychopharmacology</i> , 2012, 27, 76-90.	1.7	40
351	Mindfulness-Based Cognitive Therapy Versus Psycho-Education for Patients with Major Depression Who Did Not Achieve Remission Following Antidepressant Treatment: A Preliminary Analysis. <i>Journal of Alternative and Complementary Medicine</i> , 2012, 18, 756-760.	2.1	49
352	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. <i>Neuropsychobiology</i> , 2012, 65, 70-75.	1.9	22
353	Role of Substance Abuse Comorbidity and Personality on the Outcome of Depression in Bipolar Disorder: Harm Avoidance Influences Medium-Term Treatment Outcome. <i>Psychopathology</i> , 2012, 45, 174-178.	1.5	18
354	Antipsychotic Response in the First Week Predicts Later Efficacy. <i>Neuropsychobiology</i> , 2012, 66, 100-105.	1.9	14
355	Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis. <i>Current Alzheimer Research</i> , 2012, 9, 491-499.	1.4	13
356	Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 299-305.	1.4	22
357	P.2.a.011 Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients. <i>European Neuropsychopharmacology</i> , 2012, 22, S230.	0.7	0
358	P.3.c.044 Influence of ANKK1 and DRD2 gene polymorphisms in response to haloperidol. <i>European Neuropsychopharmacology</i> , 2012, 22, S342.	0.7	0
359	Clozapine resistance: Augmentation strategies. <i>European Neuropsychopharmacology</i> , 2012, 22, 165-182.	0.7	121
360	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder " A European Multicenter Study. <i>European Neuropsychopharmacology</i> , 2012, 22, 259-266.	0.7	38

#	ARTICLE	IF	CITATIONS
361	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. <i>European Neuropsychopharmacology</i> , 2012, 22, 239-258.	0.7	283
362	European Group for the Study of Resistant Depression (GSRD) – “Where have we gone so far: Review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012, 22, 453-468.	0.7	111
363	Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. <i>Psychiatry Research</i> , 2012, 198, 39-46.	3.3	23
364	Serum concentrations of CRP, IL-6, TNF- α and cortisol in major depressive disorder with melancholic or atypical features. <i>Psychiatry Research</i> , 2012, 198, 74-80.	3.3	138
365	Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients. <i>Psychiatry Research</i> , 2012, 200, 389-394.	3.3	96
366	Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. <i>Journal of Affective Disorders</i> , 2012, 141, 72-78.	4.1	21
367	Case-control association study of GRIA1, GRIA2 and GRIA4 polymorphisms in bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 18-26.	2.4	8
368	DAOA Variants on Diagnosis and Response to Treatment in Patients with Major Depressive Disorder and Bipolar Disorder. <i>Journal of International Medical Research</i> , 2012, 40, 258-265.	1.0	5
369	Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 147-154.	4.8	35
370	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. <i>Neuroscience Letters</i> , 2012, 506, 170-174.	2.1	15
371	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. <i>Neuroscience Letters</i> , 2012, 508, 37-41.	2.1	9
372	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , 2012, 516, 85-88.	2.1	21
373	Generalized tonic-clonic seizure secondary to duloxetine poisoning: A short report with favorable outcome. <i>NeuroToxicology</i> , 2012, 33, 189-190.	3.0	10
374	Depression across mood disorders: review and analysis in a clinical sample. <i>Comprehensive Psychiatry</i> , 2012, 53, 24-38.	3.1	34
375	Pharmacogenetics of antidepressants and mood stabilizers. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 715-744.	1.8	9
376	The 3111T/C Polymorphism Interacts With Stressful Life Events to Influence Patterns of Sleep in Females. <i>Chronobiology International</i> , 2012, 29, 891-897.	2.0	33
377	Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. <i>Neuropsychobiology</i> , 2012, 65, 1-11.	1.9	53
378	The role of serotonergic genes and environmental stress on the development of depressive symptoms and neuroticism. <i>Journal of Affective Disorders</i> , 2012, 142, 82-89.	4.1	32

#	ARTICLE	IF	CITATIONS
379	Paroxetine for the treatment of depression: a critical update. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 421-431.	1.8	176
380	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 305-311.	3.2	30
381	Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 199-205.	3.2	31
382	The challenge of uncovering the genetics of anxiety. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 185-186.	4.5	3
383	Serum Testosterone Concentration in Combat-Related Chronic Posttraumatic Stress Disorder. <i>Neuropsychobiology</i> , 2012, 65, 90-95.	1.9	23
384	No Association of a Set of Candidate Genes on Haloperidol Side Effects. <i>PLoS ONE</i> , 2012, 7, e44853.	2.5	7
385	DAO variants and schizophrenia: Influence on diagnosis and treatment outcomes. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 303-310.	2.4	4
386	Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 364-375.	2.6	40
387	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. <i>European Psychiatry</i> , 2011, 26, 1833-1833.	0.2	0
388	Clock genes and mood disorders: Which role?. <i>European Psychiatry</i> , 2011, 26, 2136-2136.	0.2	0
389	Mindfulness-Based Interventions for Chronic Pain: A Systematic Review of the Evidence. <i>Journal of Alternative and Complementary Medicine</i> , 2011, 17, 83-93.	2.1	281
390	Clinical and Demographic Predictors of Improvement during Duloxetine Treatment in Patients with Major Depression. <i>Clinical Drug Investigation</i> , 2011, 31, 385-405.	2.2	10
391	Genetics of Late-Onset Alzheimer's Disease: Update from the Alzgene Database and Analysis of Shared Pathways. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	2.0	43
392	Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines. <i>Neuropsychobiology</i> , 2011, 63, 1-7.	1.9	20
393	The CLOCK Gene and Mood Disorders: A Case-Control Study and Meta-analysis. <i>Chronobiology International</i> , 2011, 28, 825-833.	2.0	38
394	Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. <i>Clinical Psychology Review</i> , 2011, 31, 449-464.	11.4	946
395	COMT and age at onset in mood disorders: A replication and extension study. <i>Neuroscience Letters</i> , 2011, 498, 218-221.	2.1	32
396	The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotonergic systems informs a detailed genetic perspective on depressive phenotypes. <i>Progress in Neurobiology</i> , 2011, 94, 418-460.	5.7	61

#	ARTICLE	IF	CITATIONS
397	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 74-77.	4.8	6
398	Antidepressants, present and future. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1531.	4.8	1
399	Mechanisms of antidepressant action: An integrated dopaminergic perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1532-1543.	4.8	38
400	Mindfulness based cognitive therapy for psychiatric disorders: A systematic review and meta-analysis. <i>Psychiatry Research</i> , 2011, 187, 441-453.	3.3	518
401	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. <i>Psychiatry Research</i> , 2011, 188, 166-169.	3.3	10
402	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. <i>Psychiatry Research</i> , 2011, 189, 26-32.	3.3	42
403	The genetics of antipsychotic induced tremors: A genome-wide pathway analysis on the STEP-BD SCP sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 975-986.	1.7	19
404	E.02.02 Pitfalls, problems and future. <i>European Neuropsychopharmacology</i> , 2011, 21, S233-S234.	0.7	0
405	P.2.c.026 Rapid versus slow titration of paroxetine antidepressant treatment in elderly population: an observational study. <i>European Neuropsychopharmacology</i> , 2011, 21, S397-S398.	0.7	0
406	P.2.e.025 Bipolar depression: quetiapine extended release effectiveness. <i>European Neuropsychopharmacology</i> , 2011, 21, S432.	0.7	0
407	P.3.c.055 Clozapine resistance: augmentation strategies. <i>European Neuropsychopharmacology</i> , 2011, 21, S500.	0.7	3
408	A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 501-515.	2.6	37
409	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1101-1115.	3.3	64
410	A protective genetic variant for adverse environments? The role of childhood traumas and serotonin transporter gene on resilience and depressive severity in a high-risk population. <i>European Psychiatry</i> , 2011, 26, 471-478.	0.2	43
411	Sociodemographic Features Predict Antidepressant Trajectories of Response in Diverse Antidepressant Pharmacotreatment Environments. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 345-348.	1.4	11
412	A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>International Clinical Psychopharmacology</i> , 2011, 26, 130-140.	1.7	148
413	Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 512-516.	1.4	83
414	Self-Harm in Prisoners. <i>CNS Spectrums</i> , 2011, 16, 75-81.	1.2	21

#	ARTICLE	IF	CITATIONS
415	Pharmacogenetics of Antidepressants. <i>Frontiers in Pharmacology</i> , 2011, 2, 6.	3.5	72
416	Serotonin transporter gene variants and prediction of stress-induced risk for psychological distress. <i>Genes, Brain and Behavior</i> , 2011, 10, 536-541.	2.2	7
417	Is cognitive behavioural therapy an effective complement to antidepressants in adolescents? A meta-analysis. <i>Acta Neuropsychiatrica</i> , 2011, 23, 263-271.	2.1	16
418	Sexual Side Effects of Pharmacological Treatment of Psychiatric Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 142-147.	4.7	77
419	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. <i>Journal of Psychiatric Research</i> , 2011, 45, 309-321.	3.1	133
420	The influence of childhood trauma on the onset and repetition of suicidal behavior: An investigation in a high risk sample of male prisoners. <i>Journal of Psychiatric Research</i> , 2011, 45, 742-747.	3.1	67
421	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. <i>Journal of Affective Disorders</i> , 2011, 128, 56-63.	4.1	45
422	Specificity profile of paroxetine in major depressive disorder: Meta-regression of double-blind, randomized clinical trials. <i>Journal of Affective Disorders</i> , 2011, 132, 14-25.	4.1	23
423	Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. <i>Journal of Affective Disorders</i> , 2011, 135, 241-250.	4.1	29
424	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. <i>Psychopharmacology</i> , 2011, 214, 719-728.	3.1	2
425	The 5-HTTLPR polymorphism and eating disorders: A meta-analysis. <i>International Journal of Eating Disorders</i> , 2011, 44, 191-199.	4.0	77
426	Pharmacogenomics of psychotropic drugs. <i>Pharmacogenomics</i> , 2011, 12, 1509-1510.	1.3	2
427	NCAM1, TACR1 and NOS Genes and Temperament: A Study on Suicide Attempters and Controls. <i>Neuropsychobiology</i> , 2011, 64, 32-37.	1.9	12
428	Preface. <i>Neuropsychobiology</i> , 2011, 64, 127-128.	1.9	0
429	Safety and Tolerability of Lamotrigine. <i>Clinical Neuropharmacology</i> , 2011, 34, 39-47.	0.7	53
430	Neuro-imaging of mindfulness meditations: implications for clinical practice. <i>Epidemiology and Psychiatric Sciences</i> , 2011, 20, 205-210.	3.9	17
431	Factors associated with the course of symptoms in bipolar disorder during a 1-year follow-up: Depression vs. sub-threshold mixed state. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 419-426.	1.3	13
432	Pharmacogenetics of antidepressant response. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 87-113.	2.4	144

#	ARTICLE	IF	CITATIONS
433	Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenetics and Genomics, 2011, 21, 206-216.	1.5	23
434	Pharmacogenetics of antipsychotics: focus on the glutamatergic system. Pharmacopsychiatry, 2011, 44, .	3.3	0
435	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. International Clinical Psychopharmacology, 2010, 25, 297-301.	1.7	18
436	Vitamin B12 Levels in Alzheimer's Disease: Association with Clinical Features and Cytokine Production. Journal of Alzheimer's Disease, 2010, 19, 481-488.	2.6	39
437	The use of the defence style questionnaire in major depressive and panic disorders: A comprehensive meta-analysis. Psychology and Psychotherapy: Theory, Research and Practice, 2010, 83, 1-13.	2.5	50
438	HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. European Journal of Clinical Pharmacology, 2010, 66, 5-27.	1.9	30
439	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. Journal of Psychiatric Research, 2010, 44, 487-492.	3.1	23
440	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. Journal of Psychiatric Research, 2010, 44, 598-604.	3.1	25
441	APOE epsilon4 allele and cytokine production in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 338-344.	2.7	33
442	Investigation of an epistatic effect between a set of TAAR6 and HSP70 genes variations and major mood disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 680-683.	1.7	15
443	Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry, 2010, 15, 473-500.	7.9	405
444	Functional neural correlates of mindfulness meditations in comparison with psychotherapy, pharmacotherapy and placebo effect. Is there a link?. Acta Neuropsychiatrica, 2010, 22, 104-117.	2.1	36
445	Pharmacogenomics of Depression. Advances in Biological Psychiatry, 2010, , 58-74.	0.2	1
446	Pharmacogenetics of Lithium Long-Term Treatment: Focus on Initiation and Adaptation Mechanisms. Neuropsychobiology, 2010, 62, 61-71.	1.9	12
447	Weight gain in antipsychotic-naïve patients: a review and meta-analysis. Psychological Medicine, 2010, 40, 187-200.	4.5	94
448	No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. Neuropsychobiology, 2010, 62, 245-249.	1.9	5
449	No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone. International Journal of Psychiatry in Clinical Practice, 2010, 14, 228-232.	2.4	2
450	T3111C CLOCK SINGLE NUCLEOTIDE POLYMORPHISM AND MOOD DISORDERS: A META-ANALYSIS. Chronobiology International, 2010, 27, 706-721.	2.0	23

#	ARTICLE	IF	CITATIONS
451	Analysis of requirements and specifications for a monitoring system to support the self-management of dementia patients at home. , 2010, , .		3
452	No influence of FAT polymorphisms in response to aripiprazole. Journal of Human Genetics, 2010, 55, 32-36.	2.3	6
453	A systematic review of neurobiological and clinical features of mindfulness meditations. Psychological Medicine, 2010, 40, 1239-1252.	4.5	533
454	METHODS FOR OBTAINING CLINICALLY USEFUL PHARMACOGENETIC PREDICTORS; AN EXAMPLE OF A DETAILED INVESTIGATION IN AN HALOPERIDOL TREATED SAMPLE. Schizophrenia Research, 2010, 117, 130.	2.0	0
455	Predictors of Early Worsening after Switch to Aripiprazole. Clinical Drug Investigation, 2010, 30, 187-193.	2.2	13
456	MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 387-392.	4.8	35
457	Quetiapine XR: Current status for the treatment of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1165-1173.	4.8	44
458	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. Psychiatry Research, 2010, 179, 222-225.	3.3	10
459	TAAR6 variations possibly associated with antidepressant response and suicidal behavior. Psychiatry Research, 2010, 180, 20-24.	3.3	19
460	Excessive daytime sleepiness in depressed women. Psychiatry Research, 2010, 179, 171-175.	3.3	9
461	Further evidence supporting the association between 5HTR2C gene and bipolar disorder. Psychiatry Research, 2010, 180, 151-152.	3.3	7
462	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. Psychiatry Research, 2010, 178, 430-432.	3.3	9
463	Antidepressants in healthy subjects: What are the psychotropic/psychological effects?. European Neuropsychopharmacology, 2010, 20, 433-453.	0.7	54
464	<i>3111T/C CLOCK</i> GENE POLYMORPHISM IS NOT ASSOCIATED WITH SLEEP DISTURBANCES IN UNTREATED DEPRESSED PATIENTS. Chronobiology International, 2010, 27, 265-277.	2.0	34
465	No association between genetic markers inBDNFgene and lithium prophylaxis in a Greek sample. International Journal of Psychiatry in Clinical Practice, 2010, 14, 154-157.	2.4	7
466	Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance. Journal of Psychopharmacology, 2010, 24, 1747-1754.	4.0	16
467	Antidepressants and Body Weight. Journal of Clinical Psychiatry, 2010, 71, 1259-1272.	2.2	480
468	Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 Variations Does Not Impact Alcohol Dependence Disorder Features. International Journal of Environmental Research and Public Health, 2009, 6, 1980-1990.	2.6	10

#	ARTICLE	IF	CITATIONS
469	Tyrosine Hydroxylase and DOPA Decarboxylase Gene Variants in Personality Traits. <i>Neuropsychobiology</i> , 2009, 59, 23-27.	1.9	7
470	The Impact of Heat Shock Protein 70 Gene Variations on Clinical Presentation and Outcome in Schizophrenic Inpatients. <i>Neuropsychobiology</i> , 2009, 59, 135-141.	1.9	26
471	Lithium Pharmacodynamics and Pharmacogenetics: Focus on Inositol Mono Phosphatase (IMPase), Inositol Poliphosphatase (IPPase) and Glycogen Synthase Kinase 3 Beta (GSK-3 Beta). <i>Current Medicinal Chemistry</i> , 2009, 16, 1917-1948.	2.4	25
472	Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1561-1570.	1.8	57
473	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. <i>Journal of Psychiatric Research</i> , 2009, 43, 519-525.	3.1	42
474	Personality and attempted suicide. Analysis of anger, aggression and impulsivity. <i>Journal of Psychiatric Research</i> , 2009, 43, 1262-1271.	3.1	167
475	Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. <i>Journal of Affective Disorders</i> , 2009, 115, 27-35.	4.1	70
476	Depressive symptomatology is influenced by chronotypes. <i>Journal of Affective Disorders</i> , 2009, 119, 100-106.	4.1	179
477	Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. <i>Journal of Affective Disorders</i> , 2009, 119, 205-209.	4.1	39
478	Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 115-123.	1.7	89
479	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 434-438.	1.7	10
480	Focus on HTR2C: A possible suggestion for genetic studies of complex disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 601-637.	1.7	54
481	Dysbindin gene (DTNBP1) and schizophrenia in Korean population. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 137-142.	3.2	23
482	Schizophrenia: genetics, prevention and rehabilitation. <i>Acta Neuropsychiatrica</i> , 2009, 21, 109-120.	2.1	9
483	Thyroid hormones affect recovery from depression during antidepressant treatment. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 305-313.	1.8	19
484	Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 228-235.	5.6	67
485	TPH2 gene variants and anxiety during alcohol detoxification outcome. <i>Psychiatry Research</i> , 2009, 167, 106-114.	3.3	10
486	5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. <i>Psychiatry Research</i> , 2009, 167, 97-105.	3.3	25

#	ARTICLE	IF	CITATIONS
487	Influence of TAAR6 polymorphisms on response to aripiprazole. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 822-826.	4.8	9
488	TAAR 6 and HSP-70 variations associated with bipolar disorder. Neuroscience Letters, 2009, 465, 257-261.	2.1	15
489	Association between the estrogen receptor TA polymorphism and Harm avoidance. Neuroscience Letters, 2009, 467, 155-158.	2.1	16
490	Are Noradrenergic Antidepressants a Valuable Choice in the Treatment of Panic Disorder? A Review and Meta Analysis. European Psychiatry, 2009, 24, .	0.2	0
491	Interaction between SERTPR and stressful life events on response to antidepressant treatment. European Neuropsychopharmacology, 2009, 19, 64-67.	0.7	42
492	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. European Neuropsychopharmacology, 2009, 19, 562-570.	0.7	49
493	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. European Neuropsychopharmacology, 2009, 19, 718-725.	0.7	24
494	Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. European Neuropsychopharmacology, 2009, 19, 806-811.	0.7	11
495	The socio-economical burden of schizophrenia: A simulation of cost-offset of early intervention program in Italy. European Psychiatry, 2009, 24, 11-16.	0.2	21
496	Corrigendum to: "TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study" [Eur Psychiatr 2008;23:390-5]. European Psychiatry, 2009, 24, 64-64.	0.2	0
497	Mindfulness-Based Stress Reduction for Stress Management in Healthy People: A Review and Meta-Analysis. Journal of Alternative and Complementary Medicine, 2009, 15, 593-600.	2.1	1,232
498	Treatment-Emergent Sexual Dysfunction Related to Antidepressants. Journal of Clinical Psychopharmacology, 2009, 29, 259-266.	1.4	455
499	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. International Clinical Psychopharmacology, 2009, 24, 1-18.	1.7	42
500	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. International Clinical Psychopharmacology, 2009, 24, 250-256.	1.7	69
501	Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenetics and Genomics, 2009, 19, 121-128.	1.5	24
502	Lack of Association between Interleukin-1 alpha rs1800587 Polymorphism and Alzheimer's Disease in Two Independent European Samples. Journal of Alzheimer's Disease, 2009, 16, 181-187.	2.6	24
503	Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 239-244.	3.2	40
504	NOS1 and 11 gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 42-48.	1.7	50

#	ARTICLE	IF	CITATIONS
505	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 308-315.	1.7	16
506	Serotonin transporter gene and adverse life events in adult ADHD. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1461-1469.	1.7	41
507	The genetics of bipolar disorder: genome "hot regions,"™ genes, new potential candidates and future directions. Molecular Psychiatry, 2008, 13, 742-771.	7.9	175
508	Temperament and character of suicide attempters. Journal of Psychiatric Research, 2008, 42, 938-945.	3.1	63
509	DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. Neuroscience Letters, 2008, 440, 150-154.	2.1	15
510	Estrogen receptor gene 1 variants are not associated with suicidal behavior. Psychiatry Research, 2008, 160, 1-7.	3.3	14
511	Association between GSK-3 β -50T/C polymorphism and personality and psychotic symptoms in mood disorders. Psychiatry Research, 2008, 158, 132-140.	3.3	41
512	Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: One-month prospective evaluation. Psychiatry Research, 2008, 157, 269-271.	3.3	9
513	Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 375-379.	4.8	16
514	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 398-404.	4.8	126
515	Antidepressant response and intolerance to SSRI is not influenced by G-protein β 3 subunit gene C825T polymorphism in Japanese major depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1041-1044.	4.8	29
516	Acute antipsychotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1562-1566.	4.8	44
517	Psychometric characteristic of the Italian version of the Temperament and Character Inventory® Revised, personality, psychopathology, and attachment styles. Comprehensive Psychiatry, 2008, 49, 514-522.	3.1	81
518	P.1.a.006 Serotonin transporter: an example of gene influence on human behaviour. European Neuropsychopharmacology, 2008, 18, S205-S206.	0.7	0
519	P.1.a.007 A genetic assessment of antipsychotic and antidepressant cardiac iatrogenicity: focus on the proarrhythmic profile. European Neuropsychopharmacology, 2008, 18, S206.	0.7	0
520	P.2.a.015 Weight gain and antidepressants: a comprehensive review and meta analysis. European Neuropsychopharmacology, 2008, 18, S301.	0.7	1
521	P.2.c.005 Meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. European Neuropsychopharmacology, 2008, 18, S327.	0.7	1
522	Predictors of response to pharmacotherapy in mood and anxiety disorders: Commonalities, differences and indications. European Psychiatry, 2008, 23, S63.	0.2	0

#	ARTICLE	IF	CITATIONS
523	Serotonin receptor 1a, 2a, 2c and CONT SNPs and personality traits in suicide attempters and controls. European Psychiatry, 2008, 23, S171-S172.	0.2	0
524	Serotonin transporter gene and adverse life events in adult ADHD. European Psychiatry, 2008, 23, S174.	0.2	0
525	<i>TAAR6</i> variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study. European Psychiatry, 2008, 23, 390-395.	0.2	14
526	5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. International Journal of Neuropsychopharmacology, 2008, 11, 701-21.	2.1	56
527	The serotonin transporter gene and effectiveness of SSRIs. Expert Review of Neurotherapeutics, 2008, 8, 111-120.	2.8	24
528	Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics Journal, 2008, 8, 90-100.	2.0	74
529	Aripiprazole in the Treatment of Depressive and Anxiety Disorders. CNS Drugs, 2008, 22, 367-388.	5.9	66
530	Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia. Current Medicinal Chemistry, 2008, 15, 2472-2517.	2.4	6
531	Pharmacogenetics of antidepressant response: An update. Human Genomics, 2008, 3, 257.	2.9	37
532	The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Clinical Psychopharmacology, 2008, 23, 1-8.	1.7	95
533	Pharmacogenetics of Antidepressant Response. , 2008, , 315-353.		2
534	Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder. Psychiatry Investigation, 2008, 5, 102.	1.6	4
535	Personality and Genetics. Current Psychiatry Reviews, 2007, 3, 147-159.	0.9	7
536	HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies. Current Medicinal Chemistry, 2007, 14, 2053-2069.	2.4	138
537	Depression and Social Phobia Secondary to Alcohol Dependence. Neuropsychobiology, 2007, 56, 111-118.	1.9	7
538	No Association of TPH1 218A/C Polymorphism with Treatment Response and Intolerance to SSRIs in Japanese Patients with Major Depression. Neuropsychobiology, 2007, 56, 167-171.	1.9	29
539	Genetics of Alzheimer's Disease. A Rapidly Evolving Field. Journal of Alzheimer's Disease, 2007, 12, 73-92.	2.6	92
540	Reply to Comments by Dr Rico-Villademoros. Journal of Clinical Psychopharmacology, 2007, 27, 99.	1.4	2

#	ARTICLE	IF	CITATIONS
541	Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 69-75.	1.5	27
542	Incomplete Coverage of Candidate Genes: A Poorly Considered Bias. <i>Current Genomics</i> , 2007, 8, 476-483.	1.6	25
543	Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. <i>Psychiatry Research</i> , 2007, 149, 185-193.	3.3	45
544	Clinical prediction of antidepressant response in mood disorders: Linear multivariate vs. neural network models. <i>Psychiatry Research</i> , 2007, 152, 223-231.	3.3	24
545	Antidepressant response in the elderly. <i>Psychiatry Research</i> , 2007, 152, 37-44.	3.3	20
546	Heat-shock protein-70 genes and response to antidepressants in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1006-1011.	4.8	37
547	5-HT2A SNPs and the Temperament and Character Inventory. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1275-1281.	4.8	32
548	How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. <i>European Neuropsychopharmacology</i> , 2007, 17, 587-594.	0.7	55
549	S.3.2 Genetic predictors of illness and treatment response. <i>European Neuropsychopharmacology</i> , 2007, 17, S69-S70.	0.7	0
550	Further evidence of MAO-A gene variants associated with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 37-40.	1.7	17
551	<i>HTR2C</i> and <i>HTR1A</i> gene variants in German and Italian suicide attempters and completers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 291-299.	1.7	70
552	Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 701-703.	1.7	29
553	Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 631-635.	1.7	179
554	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 757-761.	1.7	17
555	Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 809-815.	1.7	46
556	Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. <i>Annals of General Psychiatry</i> , 2007, 6, 5.	2.7	10
557	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. <i>Molecular Psychiatry</i> , 2007, 12, 247-257.	7.9	487
558	HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study. <i>Molecular Psychiatry</i> , 2007, 12, 797-798.	7.9	33

#	ARTICLE	IF	CITATIONS
559	A neural network model for combining clinical predictors of antidepressant response in mood disorders. <i>Journal of Affective Disorders</i> , 2007, 98, 239-245.	4.1	19
560	Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 437.	2.1	111
561	Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1062-1070.	2.2	407
562	S.03.05 Clinical pharmacogenetic studies in the treatment of depression. <i>European Neuropsychopharmacology</i> , 2006, 16, S169.	0.7	0
563	Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. <i>Neuroscience Letters</i> , 2006, 406, 107-112.	2.1	10
564	Pooling pharmacogenetic studies on the serotonin transporter: A mega-analysis. <i>Psychiatry Research</i> , 2006, 145, 61-65.	3.3	33
565	Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: The role of clinical, psychosocial and genetic variables. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 442-448.	4.8	17
566	Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. <i>Psychiatric Genetics</i> , 2006, 16, 153-158.	1.1	48
567	Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre case-control study. <i>Psychiatric Genetics</i> , 2006, 16, 169-171.	1.1	5
568	Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. <i>Psychiatric Genetics</i> , 2006, 16, 181-182.	1.1	29
569	Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: An exploratory analysis. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 598-604.	1.8	33
570	Ethical problems in pharmacogenetic studies of psychiatric disorders. <i>Pharmacogenomics Journal</i> , 2006, 6, 289-295.	2.0	12
571	Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia. <i>Journal of Neural Transmission</i> , 2006, 113, 887-897.	2.8	14
572	Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. <i>Journal of Affective Disorders</i> , 2006, 90, 251-256.	4.1	93
573	Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre. <i>BMC Psychiatry</i> , 2006, 6, 11.	2.6	23
574	Influence of postpartum onset on the course of mood disorders. <i>BMC Psychiatry</i> , 2006, 6, 4.	2.6	19
575	Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. <i>Depression and Anxiety</i> , 2006, 23, 389-397.	4.1	43
576	Serotonin Transporter Gene Variants and Behavior: A Comprehensive Review. <i>Current Drug Targets</i> , 2006, 7, 1659-1669.	2.1	190

#	ARTICLE	IF	CITATIONS
577	Major depressive disorders: depressive disorders. , 2006, , 45-73.		0
578	Temperament and Character in Mood Disorders: Influence of DRD4, SERTPR, TPH and MAO-A Polymorphisms. Neuropsychobiology, 2006, 53, 9-16.	1.9	75
579	Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression. Journal of Clinical Psychopharmacology, 2005, 25, 471-475.	1.4	33
580	Genetics of Mood Disorders. , 2005, , 35-75.		1
581	Two new rare variants in the circadian "clock" gene may influence sleep pattern. Genetics in Medicine, 2005, 7, 455-457.	2.4	16
582	Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenetics and Genomics, 2005, 15, 61-67.	1.5	72
583	Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Molecular Psychiatry, 2005, 10, 598-605.	7.9	134
584	Dopamine transporter haplotype and attention-deficit hyperactivity disorder. Molecular Psychiatry, 2005, 10, 617-618.	7.9	23
585	Profiles of "manic" symptoms in bipolar I, bipolar II and major depressive disorders. Journal of Affective Disorders, 2005, 84, 159-166.	4.1	85
586	Components of self-esteem in affective patients and non-psychiatric controls. Journal of Affective Disorders, 2005, 88, 93-98.	4.1	28
587	5-HT1A polymorphism and self-transcendence in mood disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 33-35.	1.7	26
588	Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 36-39.	1.7	146
589	Genes involved in Alzheimer's disease, a survey of possible candidates. Journal of Alzheimer's Disease, 2005, 7, 331-353.	2.6	30
590	Interaction between the Tryptophan Hydroxylase Gene and the Serotonin Transporter Gene in Schizophrenia but Not in Bipolar or Unipolar Affective Disorders. Neuropsychobiology, 2005, 51, 3-9.	1.9	15
591	Occurrence of Cognitive Impairment and Dementia after the Age of 60: A Population-Based Study from Northern Italy. Dementia and Geriatric Cognitive Disorders, 2005, 19, 97-105.	1.5	88
592	Cognitive Status, Depressive Symptoms, and Health Status as Predictors of Functional Disability Among Elderly Persons With Low-to-Moderate Education: The Faenza Community Aging Study. American Journal of Geriatric Psychiatry, 2005, 13, 672-685.	1.2	16
593	Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3- β \sim 50 T/C SNP. Neuroscience Letters, 2005, 376, 51-55.	2.1	184
594	No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia. Neuroscience Research, 2005, 52, 195-199.	1.9	14

#	ARTICLE	IF	CITATIONS
595	Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. Neuroscience Research, 2005, 53, 8-13.	1.9	34
596	The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1074-1084.	4.8	104
597	Social adjustment could be associated with the serotonin transporter gene in remitted patients with mood disorders and healthy subjects. Psychiatry Research, 2005, 134, 191-194.	3.3	11
598	New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects. Current Medicinal Chemistry, 2004, 11, 343-358.	2.4	102
599	Polymorphism of the Cytosolic Phospholipase A ₂ Gene and Mood Disorders in the Korean Population. Neuropsychobiology, 2004, 49, 185-188.	1.9	37
600	The 5-HT _{2C} receptor as a target for mood disorders. Expert Opinion on Therapeutic Targets, 2004, 8, 15-23.	3.4	48
601	Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. European Journal of Human Genetics, 2004, 12, 377-382.	2.8	78
602	The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics Journal, 2004, 4, 233-244.	2.0	66
603	Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics Journal, 2004, 4, 267-273.	2.0	55
604	Social adjustment and self-esteem of bipolar patients: a multicentric study. Journal of Affective Disorders, 2004, 79, 97-103.	4.1	92
605	From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology, 2004, 174, 490-503.	3.1	52
606	Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology, 2004, 174, 504-11.	3.1	42
607	Neural network analysis in pharmacogenetics of mood disorders. BMC Medical Genetics, 2004, 5, 27.	2.1	49
608	Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American Journal of Medical Genetics Part A, 2004, 129B, 36-40.	2.4	66
609	Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Human Psychopharmacology, 2004, 19, 25-29.	1.5	8
610	Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Research, 2004, 125, 65-68.	3.3	36
611	Dimensions of major psychoses: a confirmatory factor analysis of six competing models. Psychiatry Research, 2004, 127, 101-109.	3.3	56
612	Depressive syndrome in major psychoses: a study on 1351 subjects. Psychiatry Research, 2004, 127, 85-99.	3.3	60

#	ARTICLE	IF	CITATIONS
613	Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. <i>Psychiatry Research</i> , 2004, 127, 279-281.	3.3	33
614	A single nucleotide polymorphism in glycogen synthase kinase 3- β promoter gene influences onset of illness in patients affected by bipolar disorder. <i>Neuroscience Letters</i> , 2004, 355, 37-40.	2.1	156
615	DRD4 exon 3 variants are not associated with symptomatology of major psychoses in a German population. <i>Neuroscience Letters</i> , 2004, 368, 269-273.	2.1	5
616	A glycogen synthase kinase 3- β promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. <i>Neuroscience Letters</i> , 2004, 368, 123-126.	2.1	189
617	Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , 2004, 14, 65-67.	1.1	14
618	Pharmacogenetics of selective serotonin reuptake inhibitor response. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 607-613.	5.7	30
619	The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 453-460.	2.1	119
620	Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 489-493.	2.1	45
621	Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , 2004, 14, 147-150.	1.1	31
622	The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach. <i>Current Genomics</i> , 2004, 5, 499-508.	1.6	2
623	Influence of <i>CLOCK</i> gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. <i>American Journal of Medical Genetics Part A</i> , 2003, 123B, 23-26.	2.4	272
624	Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and <i>CLOCK</i> gene polymorphism. <i>American Journal of Medical Genetics Part A</i> , 2003, 121B, 35-38.	2.4	228
625	Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 153-159.	1.8	17
626	Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 399-403.	1.8	27
627	Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study. <i>European Neuropsychopharmacology</i> , 2003, 13, 365-368.	0.7	20
628	Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. <i>Biological Psychiatry</i> , 2003, 54, 687-692.	1.3	83
629	TNFB polymorphism may be associated with schizophrenia in the Korean population. <i>Schizophrenia Research</i> , 2003, 61, 39-45.	2.0	17
630	SSRIs antidepressant activity is influenced by G β 3 variants. <i>European Neuropsychopharmacology</i> , 2003, 13, 117-122.	0.7	88

#	ARTICLE	IF	CITATIONS
631	Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 519-523.	4.8	22
632	Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 751-757.	4.8	31
633	Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. Psychiatry Research, 2003, 118, 241-247.	3.3	23
634	Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. Psychiatry Research, 2003, 119, 99-111.	3.3	76
635	Predicting Response to Lithium in Mood Disorders. Molecular Diagnosis and Therapy, 2003, 3, 17-30.	3.3	26
636	VNTR Polymorphism of Tyrosine Hydroxylase Gene and Schizophrenia in the Korean Population. Neuropsychobiology, 2003, 47, 131-136.	1.9	7
637	Polymorphism of the Serotonin Transporter Gene and Symptomatic Dimensions of Schizophrenia in the Korean Population. Neuropsychobiology, 2003, 47, 182-186.	1.9	17
638	Title is missing!. Psychiatric Genetics, 2003, 13, 121-126.	1.1	4
639	Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case-control study. Psychiatric Genetics, 2003, 13, 211-220.	1.1	22
640	Possible association between TNF- α G308A tumour necrosis factor- α gene polymorphism and major depressive disorder in the Korean population. Psychiatric Genetics, 2003, 13, 179-181.	1.1	107
641	Comparison of Response to Fluvoxamine in Nondemented Elderly Compared to Younger Patients Affected by Major Depression. Journal of Clinical Psychopharmacology, 2003, 23, 535-539.	1.4	26
642	Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatric Genetics, 2003, 13, 121-126.	1.1	26
643	Excess of allele1 for $\alpha 3$ subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Molecular Psychiatry, 2002, 7, 201-207.	7.9	51
644	Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. International Journal of Neuropsychopharmacology, 2002, 5, 27-35.	2.1	91
645	Serotonin transporter gene (5-HTTLPR) and major psychoses. Molecular Psychiatry, 2002, 7, 95-99.	7.9	79
646	Lithium long-term treatment in mood disorders: clinical and genetic predictors. Pharmacogenomics, 2002, 3, 117-129.	1.3	13
647	Clinical and demographic features of mood disorder subtypes. Psychiatry Research, 2002, 112, 195-210.	3.3	55
648	Rapid cycling mood disorder: Clinical and demographic features. Comprehensive Psychiatry, 2002, 43, 336-343.	3.1	22

#	ARTICLE	IF	CITATIONS
649	Seasonal variations of lithium plasma levels. <i>Psychiatry Research</i> , 2002, 111, 35-41.	3.3	14
650	Pharmacogenetics in affective disorders. <i>European Journal of Pharmacology</i> , 2002, 438, 117-128.	3.5	55
651	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 177-185.	2.4	50
652	Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 361-369.	2.4	57
653	Pharmacogenetics of lithium prophylaxis in mood disorders: Analysis of COMT, MAO-A, and G123 variants. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 370-379.	2.4	50
654	Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 380-390.	2.4	47
655	Serotonin transporter gene (5-HTTLPR) and major psychoses. <i>Molecular Psychiatry</i> , 2002, 7, 95-99.	7.9	6
656	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 177-85.	2.4	10
657	Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. <i>European Neuropsychopharmacology</i> , 2001, 11, 375-380.	0.7	103
658	Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. <i>Biological Psychiatry</i> , 2001, 49, 405-409.	1.3	66
659	Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. <i>Biological Psychiatry</i> , 2001, 50, 323-330.	1.3	213
660	Tryptophan hydroxylase gene and major psychoses. <i>Psychiatry Research</i> , 2001, 103, 79-86.	3.3	48
661	No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. <i>Psychiatry Research</i> , 2001, 104, 195-203.	3.3	54
662	Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 193-198.	3.2	38
663	DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: A study on 2,011 affected subjects. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 283-290.	2.4	60
664	Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. <i>Molecular Psychiatry</i> , 2001, 6, 586-592.	7.9	169
665	Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. <i>Molecular Psychiatry</i> , 2001, 6, 579-585.	7.9	150
666	Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. <i>Journal of Psychiatric Research</i> , 2001, 35, 217-223.	3.1	40

#	ARTICLE	IF	CITATIONS
667	Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics Journal, 2001, 1, 71-77.	2.0	107
668	"Dr. Zanardi and Colleagues Reply". Journal of Clinical Psychiatry, 2001, 62, 296.	2.2	1
669	Melancholic features and response to lithium prophylaxis in mood disorders. Depression and Anxiety, 2000, 11, 73-79.	4.1	18
670	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. , 2000, 96, 84-87.		20
671	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. , 2000, 96, 136-140.		38
672	Serotonin-2C and serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders. , 2000, 96, 161-166.		19
673	Effect of reboxetine augmentation in SSRI resistant patients. , 2000, 15, 143-145.		17
674	Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Molecular Psychiatry, 2000, 5, 270-274.	7.9	57
675	Linkage of mood disorders with D2, D3 and TH genes: a multicenter study. Journal of Affective Disorders, 2000, 58, 51-61.	4.1	28
676	Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. Journal of Psychiatric Research, 2000, 34, 89-98.	3.1	66
677	Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Research, 2000, 94, 185-190.	3.3	31
678	Impact of clinical variables on illness time course in mood disorders. Psychiatry Research, 2000, 97, 217-227.	3.3	27
679	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. American Journal of Medical Genetics Part A, 2000, 96, 136-140.	2.4	2
680	Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression. Journal of Clinical Psychiatry, 2000, 61, 26-29.	2.2	216
681	Adaptación social y autoestima en pacientes con remisión de trastorno del estado de ánimo. European Psychiatry (Ed Española), 2000, 7, 26-32.	0.0	0
682	Dr. Benedetti and Colleagues Reply. American Journal of Psychiatry, 2000, 157, 1887-1888.	7.2	0
683	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. American Journal of Medical Genetics Part A, 2000, 96, 84-7.	2.4	2
684	Further evidence supporting the association between the dopamine receptor D2 Ser/Cys311 variant and disorganized symptomatology of schizophrenia. Schizophrenia Research, 2000, 43, 161-2.	2.0	8

#	ARTICLE	IF	CITATIONS
685	Genetic Variants of Dopamine Receptor D4 and Psychopathology. Schizophrenia Bulletin, 1999, 25, 609-618.	4.3	34
686	Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Molecular Psychiatry, 1999, 4, 280-283.	7.9	94
687	Symptomatologic analysis of psychotic and non-psychotic depression. Journal of Affective Disorders, 1999, 54, 183-187.	4.1	60
688	Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression. Journal of Affective Disorders, 1999, 56, 17-25.	4.1	49
689	Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders ¹¹ This work was partially supported by the BIOMED 2 grant BMH4-CT97-2307.. Journal of Psychiatric Research, 1999, 33, 371-377.	3.1	82
690	No interaction of GABAA alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. , 1999, 88, 44-49.		18
691	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. American Journal of Medical Genetics Part A, 1999, 88, 294-297.	2.4	16
692	Dopamine D3 receptor gene not associated with symptomatology of major psychoses. , 1999, 88, 476-480.		14
693	No interaction between serotonin transporter gene and dopamine receptorD4 gene in symptomatology of major psychoses. , 1999, 88, 481-485.		11
694	Dopamine receptorD4 gene is not associated with major psychoses. , 1999, 88, 486-491.		24
695	Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: A multicenter association study. , 1999, 88, 527-532.		17
696	Outcome of affective psychosis. , 1999, 10, 50-54.		6
697	Serotonin transporter gene not associated with psychotic symptomatology of mood disorders. Psychiatry Research, 1999, 86, 59-65.	3.3	24
698	No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders. Psychiatry Research, 1999, 86, 203-209.	3.3	14
699	Dopamine receptor D2 and D4 genes, GABAA alpha-1 subunit gene and response to lithium prophylaxis in mood disorders. Psychiatry Research, 1999, 87, 7-19.	3.3	66
700	Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation. Psychiatry Research, 1999, 89, 107-114.	3.3	28
701	Factor analysis of delusional disorder symptomatology. Comprehensive Psychiatry, 1999, 40, 143-147.	3.1	42
702	Clinical and demographic features of psychotic and nonpsychotic depression. Comprehensive Psychiatry, 1999, 40, 358-362.	3.1	33

#	ARTICLE	IF	CITATIONS
703	Serotonin transporter gene is not associated with symptomatology of schizophrenia. Schizophrenia Research, 1999, 35, 33-39.	2.0	33
704	Lack of association between tryptophan hydroxylase gene and psychotic symptomatology in schizophrenia. Schizophrenia Research, 1999, 40, 171-172.	2.0	6
705	Social adjustment and self-esteem in remitted patients with mood disorders. European Psychiatry, 1999, 14, 137-142.	0.2	37
706	Factor Analysis of Mania. Archives of General Psychiatry, 1999, 56, 671.	12.3	36
707	No interaction of GABA(A) alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. American Journal of Medical Genetics Part A, 1999, 88, 44-9.	2.4	2
708	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. American Journal of Medical Genetics Part A, 1999, 88, 294-7.	2.4	1
709	Outcome of affective psychosis. Depression and Anxiety, 1999, 10, 50-4.	4.1	1
710	Influence of a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene on the Effects of Total Sleep Deprivation in Bipolar Depression. American Journal of Psychiatry, 1999, 156, 1450-1452.	7.2	145
711	Tyrosine hydroxylase gene in linkage disequilibrium with mood disorders. Molecular Psychiatry, 1998, 3, 169-174.	7.9	18
712	Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research, 1998, 32, 255-259.	3.1	148
713	Mode of inheritance in mood disorder families according to fluvoxamine response. Acta Psychiatrica Scandinavica, 1998, 98, 443-450.	4.5	55
714	Analysis of depressive symptomatology in mood disorders. Depression and Anxiety, 1998, 8, 80-85.	4.1	34
715	Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. , 1998, 81, 127-130.		53
716	Dopamine receptor D4 gene is associated with delusional symptomatology in mood disorders. Psychiatry Research, 1998, 80, 129-136.	3.3	36
717	Self-esteem in remitted patients with mood disorders is not associated with the dopamine receptor D4 and the serotonin transporter genes. Psychiatry Research, 1998, 80, 137-144.	3.3	7
718	Dopamine receptor D2 Ser/Cys311 variant associated with disorganized symptomatology of schizophrenia. Schizophrenia Research, 1998, 34, 207-210.	2.0	41
719	Psychopathology of dysthymia. European Psychiatry, 1998, 13, 258s-258s.	0.2	0
720	Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. International Journal of Neuropsychopharmacology, 1998, 1, 125-129.	2.1	45

#	ARTICLE	IF	CITATIONS
721	European Collaborative Project on Affective Disorders. <i>Psychiatric Genetics</i> , 1998, 8, 197-205.	1.1	41
722	GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. <i>Psychiatric Genetics</i> , 1998, 8, 251-254.	1.1	22
723	Analysis of depressive symptomatology in mood disorders. <i>Depression and Anxiety</i> , 1998, 8, 80-5.	4.1	4
724	S.17.05 Molecular genetics of bipolar disorders: Implication for psychotropic drugs. <i>European Neuropsychopharmacology</i> , 1997, 7, S112-S113.	0.7	6
725	Evidence for an Association between the Dopamine D3 Receptor Gene DRD3 and Schizophrenia. <i>Human Heredity</i> , 1997, 47, 6-16.	0.8	52
726	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. <i>International Clinical Psychopharmacology</i> , 1996, 11, 109-117.	1.7	14
727	Identification of symptomatologic patterns common to major psychoses: Proposal for a phenotype definition. <i>American Journal of Medical Genetics Part A</i> , 1996, 67, 393-400.	2.4	60
728	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. <i>International Clinical Psychopharmacology</i> , 1996, 11, 109-117.	1.7	39
729	Symptomatologic structure extraction of major psychosis and association with DRD4 exon 1 and 3 variants. <i>Behavioural Pharmacology</i> , 1995, 6, 69.	1.7	0
730	Positive association between bipolar affective disorder and tyrosine hydroxylase gene. <i>Behavioural Pharmacology</i> , 1995, 6, 124.	1.7	0
731	Low-dose buprenorphine detoxification in long term methadone addicts. <i>Regulatory Peptides</i> , 1994, 53, S289-S290.	1.9	5
732	Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. <i>Drug and Alcohol Dependence</i> , 1994, 36, 139-145.	3.2	71
733	"Separation" of the mother-child couple: pregnancy and maternity of drug-dependent women. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1994, 83, 47-53.	1.5	7
734	Gene-Environment Interaction Studies in Suicidal Behaviour. <i>Advances in Biological Psychiatry</i> , 0, , 63-74.	0.2	0
735	Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 0, Publish Ahead of Print, .	1.7	2